- Home
- CMPS vs UPXI Comparison
CMPS vs UPXI Comparison
Compare CMPS & UPXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPS
- UPXI
- Stock Information
- Founded
- CMPS 2020
- UPXI 2018
- Country
- CMPS United Kingdom
- UPXI United States
- Employees
- CMPS N/A
- UPXI N/A
- Industry
- CMPS Biotechnology: Pharmaceutical Preparations
- UPXI Medicinal Chemicals and Botanical Products
- Sector
- CMPS Health Care
- UPXI Health Care
- Exchange
- CMPS Nasdaq
- UPXI Nasdaq
- Market Cap
- CMPS 598.7M
- UPXI 481.8M
- IPO Year
- CMPS 2020
- UPXI 2021
- Fundamental
- Price
- CMPS $5.31
- UPXI $2.71
- Analyst Decision
- CMPS Strong Buy
- UPXI Buy
- Analyst Count
- CMPS 8
- UPXI 1
- Target Price
- CMPS $16.43
- UPXI $6.00
- AVG Volume (30 Days)
- CMPS 2.1M
- UPXI 4.5M
- Earning Date
- CMPS 11-04-2025
- UPXI 11-11-2025
- Dividend Yield
- CMPS N/A
- UPXI N/A
- EPS Growth
- CMPS N/A
- UPXI N/A
- EPS
- CMPS N/A
- UPXI 1.85
- Revenue
- CMPS N/A
- UPXI $20,694,575.00
- Revenue This Year
- CMPS N/A
- UPXI $145.75
- Revenue Next Year
- CMPS N/A
- UPXI N/A
- P/E Ratio
- CMPS N/A
- UPXI $1.45
- Revenue Growth
- CMPS N/A
- UPXI N/A
- 52 Week Low
- CMPS $2.25
- UPXI $1.90
- 52 Week High
- CMPS $7.09
- UPXI $22.57
- Technical
- Relative Strength Index (RSI)
- CMPS 41.21
- UPXI 30.09
- Support Level
- CMPS $5.01
- UPXI $2.58
- Resistance Level
- CMPS $6.01
- UPXI $3.65
- Average True Range (ATR)
- CMPS 0.47
- UPXI 0.35
- MACD
- CMPS -0.09
- UPXI -0.02
- Stochastic Oscillator
- CMPS 15.78
- UPXI 7.59
About CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of major depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.
About UPXI Upexi Inc.
Upexi Inc specializes in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space via a Solana treasury strategy.